TERT promotor status does not add prognostic information in IDH-wildtype glioblastomas fulfilling other diagnostic WHO criteria: A report of the RANO resect group
Karschnia P, Young JS, Dono A, Häni L, Juenger ST, Sciortino T, Bruno F, Teske N, Morshed RA, Haddad AF, Zhang Y, Stoecklein S, Vogelbaum MA, Beck J, Tandon N, Hervey-Jumper S, Molinaro AM, Rudà R, Bello L, Schnell O, Esquenazi Y, Ruge MI, Grau SJ, Van Den Bent M, Weller M, Berger MS, Chang SM, Tonn JC (2022)
Publication Type: Journal article
Publication year: 2022
Journal
Book Volume: 4
Article Number: vdac158
Journal Issue: 1
Abstract
In IDH-wildtype glioblastomas which meet the histopathological or molecular diagnosis criteria, it remains unclear whether the presence of TERT promotor mutations provides additional prognostic information. Based on a multicenter cohort of 466 IDH-wildtype glioblastomas (including 396 with and 70 patients without TERT promotor mutations), we found that TERT promotor mutations were neither associated with progression-free survival nor overall survival. This held true in various treatment-based or molecular subgroups. This argues against standardized analysis for TERT promotor mutation status for the purpose of prognostic or therapeutic relevance in newly diagnosed IDH-wildtype glioblastoma that otherwise meets the histopathological and molecular diagnosis criteria.
Authors with CRIS profile
Involved external institutions
H. Lee Moffitt Cancer Center & Research Institute
United States (USA) (US)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
University of San Francisco (USF)
United States (USA) (US)
University of Texas Health Science Center at Houston (UTHealth)
United States (USA) (US)
Universitätsklinikum Freiburg
Germany (DE)
Universität zu Köln
Germany (DE)
Università degli studi di Milano
Italy (IT)
University of Turin / Università degli Studi di Torino (UNITO)
Italy (IT)
Klinikum der Universität München
Germany (DE)
Universitätsklinikum Köln
Germany (DE)
Erasmus University Medical Center (MC)
Netherlands (NL)
Universitätsspital Zürich (USZ)
Switzerland (CH)
United States (USA) (US)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
University of San Francisco (USF)
United States (USA) (US)
University of Texas Health Science Center at Houston (UTHealth)
United States (USA) (US)
Universitätsklinikum Freiburg
Germany (DE)
Universität zu Köln
Germany (DE)
Università degli studi di Milano
Italy (IT)
University of Turin / Università degli Studi di Torino (UNITO)
Italy (IT)
Klinikum der Universität München
Germany (DE)
Universitätsklinikum Köln
Germany (DE)
Erasmus University Medical Center (MC)
Netherlands (NL)
Universitätsspital Zürich (USZ)
Switzerland (CH)
How to cite
APA:
Karschnia, P., Young, J.S., Dono, A., Häni, L., Juenger, S.T., Sciortino, T.,... Tonn, J.C. (2022). TERT promotor status does not add prognostic information in IDH-wildtype glioblastomas fulfilling other diagnostic WHO criteria: A report of the RANO resect group. Neuro-Oncology Advances, 4(1). https://doi.org/10.1093/noajnl/vdac158
MLA:
Karschnia, Philipp, et al. "TERT promotor status does not add prognostic information in IDH-wildtype glioblastomas fulfilling other diagnostic WHO criteria: A report of the RANO resect group." Neuro-Oncology Advances 4.1 (2022).
BibTeX: Download